Cryoport, Inc. (CYRX) Q2 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025. Cryoport, Inc. is a global provider of temperature-controlled supply chain solutions for the life sciences industry, focusing on regenerative medicine. The reporting period is significantly impacted by the completion of the divestiture of its specialty courier business, CRYOPDP, to affiliates of DHL Supply Chain on June 11, 2025. Consequently, CRYOPDP results are classified as discontinued operations.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenue (Continuing Ops) | $45.5 million | $39.7 million | $86.5 million | $77.0 million |
| Gross Margin | $21.4 million (47.0%) | $17.7 million (44.5%) | $40.0 million (46.3%) | $32.7 million (42.5%) |
| Loss from Continuing Operations | $(12.0) million | $(76.4) million | $(18.8) million | $(91.5) million |
| Income from Discontinued Ops | $117.2 million | $(1.6) million | $112.0 million | $(5.4) million |
| Net Income (Loss) | $105.2 million | $(78.0) million | $93.2 million | $(96.9) million |
| Cash and Cash Equivalents | $243.4 million (as of June 30, 2025) | |||
| Short-term Investments | $182.6 million (as of June 30, 2025) | |||
| Convertible Senior Notes (Long-term) | $184.5 million (as of June 30, 2025) |
Material Changes vs. Prior Period
- Divestiture Impact: The sale of CRYOPDP generated a gain of approximately $116.7 million, recorded in discontinued operations. This resulted in a net income of $105.2 million for Q2 2025, a stark contrast to the net loss of $78.0 million in Q2 2024.
- Continuing Operations Performance: Excluding discontinued operations, the company reduced its loss from continuing operations by 84.3% year-over-year (from $76.4M loss to $12.0M loss). This improvement is largely due to the absence of a $63.8 million goodwill impairment charge recorded in Q2 2024 related to the MVE reporting unit.
- Revenue Growth: Continuing operations revenue grew 14.5% in Q2 and 12.3% YTD. Life Sciences Services revenue grew 20.9% (Q2) and 19.2% (YTD), driven by BioLogistics and BioStorage/BioServices. Life Sciences Products revenue grew 7.8% (Q2) and 5.1% (YTD).
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 11.3% YTD, primarily due to a $4.5 million decrease in contingent consideration and a $3.1 million decrease in stock-based compensation.
- Debt Repayment: The company repaid the $14.3 million 2025 Convertible Senior Notes upon maturity in June 2025. The 2026 Senior Notes remain outstanding at $186.2 million principal.
Guidance, Outlook, and Risks
- Strategic Partnership: The divestiture includes a strategic partnership with DHL, expected to enhance Cryoport's capabilities in EMEA and APAC regions.
- Capital Allocation: The company has approximately $69.7 million remaining under its stock repurchase programs. In Q2 2025, it repurchased 628,217 shares for $4.2 million. Subsequent events note an additional $2.7 million in repurchases in July 2025.
- Liquidity: Management believes current cash, short-term investments, and projected cash flows will satisfy operational requirements for at least the next 12 months.
- Risks: Key risks include foreign currency fluctuations (impacting revenue translation and intercompany balances), inflationary pressures on labor and freight costs, and the ability to successfully integrate the new DHL partnership. The company also faces potential risks related to the valuation of contingent consideration liabilities.
- Tax Legislation: New U.S. tax reform legislation (Public Law 119-21) signed on July 4, 2025, is being evaluated, though management does not expect a material impact on financial statements.
Investor Verification Checklist
- Discontinued Operations: Verify the sustainability of the $117M gain from the CRYOPDP sale; this is a one-time event and does not reflect recurring operating performance.
- Continuing Operations Loss: Analyze the path to profitability for continuing operations, which still reported a loss of $12.0M in Q2 despite revenue growth.
- Debt Obligations: Confirm the terms and maturity of the remaining $186.2M in 2026 Convertible Senior Notes and the impact of interest rates on fair value.
- Stock Repurchases: Monitor the remaining $69.7M authorization and the company's commitment to returning capital versus investing in growth.
- Foreign Exchange: Assess the impact of currency fluctuations on the 24-27% of revenue generated from international customers (EMEA and APAC).